September 16, 2021

Assessing Clinical Response to Treatment in Psoriatic Arthritis

Patient reported outcomes differentiate between remission and low disease activity in PsA

21-RHE-2356408-Hero-ImageOpt2-650×450

By Elaine Husni, MD, MPH, and Juliette Yedimenko, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In psoriatic arthritis (PsA), multiple composite measures exist to assess disease activity, and no particular one is considered the gold standard. The composite measures assess various combinations of PsA features, including tender and swollen joints, skin involvement, dactylitis and enthesitis and inflammation markers, with limited patient and physician assessment. Patient-reported outcomes (PROs) can also provide useful information on the patient’s perception of disease and the residual impact on their function and quality of life. However, few studies evaluate PROs in the setting of PsA remission.

In order to assess how clinical disease activity measures compare with PROs for patients who have low disease activity (LDA) or are in remission, we conducted a cross-sectional study using the Psoriatic Arthritis Research Consortium cohort and presented the results at the 2020 Annual Meeting of the American College of Rheumatology.

Clinical disease activity measures vs. patient-reported measures

Specifically, we examined the ability of the Patient-Reported Outcomes Measurement Information System (PROMIS), the Routine Assessment of Patient Index Data 3 (RAPID3) and the European League Against Rheumatism Psoriatic Arthritis Impact of Disease (PSAID12) instruments to differentiate between states of LDA and remission (REM). For this study, patients with LDA fulfilled the composite index criteria for Minimal Disease Activity (MDA), Clinical Disease Activity Index (CDAI)-LDA or Disease Activity in Psoriatic Arthritis (cDAPSA-LDA). Patients were considered in remission if they fulfilled composite index criteria for very low disease activity (VLDA), CDAI-REM or cDAPSA-REM.

Advertisement

In our cohort of 227 patients (52.2% female, average age 52.7 ± 14 years), PROMIS and PSAID12 scores correlated with composite indexes. Our findings indicate that PROs were able to distinguish a statistically significant difference in patient disease activity, when comparing patients reaching LDA and REM. Patients who were able reach a REM score reported better functioning and outcomes in their PROs scores compared with those with LDA.

Consider PROs when establishing treatment targets

Clinical exam and laboratory data within normal limits do not necessarily reflect the absence of additional disease-related symptoms or residual impact on a patient’s function and quality of life, which should be considered when establishing treatment targets. Our data contribute to the construct validity of using PROs to measure low states of disease activity and may be very useful in the establishment of comprehensive treatment targets in PsA.

These findings are significant because there may be a tendency for clinicians to settle for LDA based on current measures. However, patients could reach even more stringent criteria of remission if PROs were included. As always, the risks and side effects of any treatment must still be weighed against the potential for further gain in controlling disease activity.

Advertisement

Additionally, composite measures often require specific laboratory data that may not be readily available at time of the visit. The advantage of this strong correlation between PROs and the composite indices is that it may facilitate the use of PROs as an acceptable surrogate marker of disease activity and may be more practical in some settings to guide treatment at point of care.

Dr. Husni is Vice Chair of the Department of Rheumatic and Immunologic Diseases. Dr. Yedimenko is staff in the department.

Related Articles

psoriasis of the fingernails and psoriatic arthritis on white background
July 15, 2022
Using Patient-Reported Outcomes to Distinguish Between Low Disease Activity and Remission in Psoriatic Arthritis

Patient perceptions of disease provides valuable dimension to assessment

18-HRT-411-aspirin-650×450
May 22, 2019
A Simple Clinical Risk Score for Major NSAID Toxicity

Evidence-based, internally validated method for risk evaluation

18-RHE-1125-Husni-Hero-Image-650x450pxl
October 26, 2018
Practice-Changing PRECISION Subanalyses

What rheumatologists should know

back pain
January 18, 2017
Searching for Spondyloarthritis in a Diagnostic Dead Zone

Where are the patients?

15-RHE-2814-Husni-Image-650x450pxl
November 10, 2016
Tapering DMARDs: Where are we now?

Raising more questions than answers

15-RHE-2599-Chatterjee-Hero-Image-690x380pxl
November 11, 2015
Lung Effects of Anti-PM-Scl Antibody: Analysis Yields Important Questions for Prospective Study

New insights into PAH and ILD in patients with the antibody

15-RHE-532-Husni-Hero-Image-690x380pxl
April 29, 2015
Guidance at Last on Managing Comorbidities of Psoriatic Arthritis

GRAPPA provides first expert recommendations

Medical illustration of hand with discolored fingers
February 27, 2024
Coexistence of Erythromelalgia and Raynaud’s Phenomenon

Treatment strategies require understanding of pathomechanisms

Ad